Laboratory Monitoring After Starting Kerendia (Finerenone)
Check serum potassium at 1 month after initiation, then every 4 months during ongoing treatment. 1
Initial Monitoring Protocol
The KDIGO 2024 guidelines provide explicit monitoring recommendations for finerenone:
- At 1 month post-initiation: Check serum potassium
- Every 4 months thereafter: Continue regular potassium monitoring during maintenance therapy
This monitoring schedule applies regardless of whether you're maintaining the initial dose or uptitrating from 10 mg to 20 mg daily. 1
Potassium-Based Management Algorithm
The monitoring isn't just about checking labs—it's about acting on the results:
If K+ ≤4.8 mmol/L (≤4.8 mEq/L):
- Continue finerenone at current dose (10 mg or 20 mg)
- If patient is on 10 mg daily, uptitrate to 20 mg daily
- Continue monitoring every 4 months
If K+ 4.9-5.5 mmol/L:
- Continue finerenone at current dose
- Do not uptitrate if on 10 mg
- Monitor potassium every 4 months
If K+ >5.5 mmol/L:
- Hold finerenone immediately
- Address hyperkalemia through dietary modifications or adjustment of concomitant medications
- Recheck potassium
- Restart at 10 mg daily when K+ ≤5.0 mmol/L 1, 2
Additional Laboratory Considerations
While potassium is the primary lab requiring specific monitoring intervals, you should also track:
eGFR: Continue routine CKD monitoring per your usual schedule (typically every 3-12 months depending on CKD stage). Finerenone initiation does not necessitate more frequent eGFR monitoring. 1
UACR (urine albumin-to-creatinine ratio): Monitor as part of standard CKD care to assess treatment response, though no specific finerenone-related monitoring interval is mandated by guidelines.
Critical Pitfalls to Avoid
Don't discontinue finerenone for mild potassium elevations. The 4.9-5.5 mmol/L range is a "continue and monitor" zone, not a discontinuation threshold. Only hold the medication when potassium exceeds 5.5 mmol/L. 1
Don't forget the 1-month check. This is when hyperkalemia is most likely to manifest. Real-world data shows hyperkalemia occurs in approximately 8-10% of patients, but severe cases requiring hospitalization are rare (0.3%). 3, 4
Don't assume you need to check potassium more frequently than every 4 months after the initial month unless clinical circumstances change (e.g., acute illness, addition of other potassium-affecting medications, or development of hyperkalemia).
Real-World Context
Recent real-world studies confirm that this monitoring schedule is practical and safe. In the FINE-REAL study of nearly 2,000 patients, hyperkalaemia occurred in 8% of participants but led to discontinuation in only 1% and hospitalization in 0.3%, with no fatal cases. 3 The FOUNTAIN platform study showed even lower rates with hyperkalemia occurring in just 1.2% of patients at 12 months. 5
The bottom line: Potassium at 1 month, then every 4 months. This simple schedule, combined with the action thresholds above, allows safe and effective use of finerenone while minimizing the risk of clinically significant hyperkalemia.